Pf4-KO Mouse
一般名
Pf4-KO
製品ID
S-KO-10928
背景情報
C57BL/6JCya
系統ID
KOCMP-56744-Pf4-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Pf4-KO Mouse(カタログ番号S-KO-10928)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Pf4-KO
系統ID
KOCMP-56744-Pf4-B6J-VA
遺伝子名
製品ID
S-KO-10928
遺伝子別名
Cxcl4, Scyb4
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 5
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000031320
NCBIトランスクリプトID
NM_019932
ターゲット領域
Exon 1~3
有効領域の大きさ
~1.5 kb
遺伝子研究の概要
Pf4, also known as Platelet factor 4 or chemokine (C-X-C motif) ligand 4 (CXCL4), is a highly cationic tetrameric protein and an abundant chemokine released from platelet α -granules on activation. It is central to blood coagulation and also involved in innate and adaptive immunity when platelets respond to infections [1,2,3,7]. PF4 binds and activates the thrombopoietin receptor c -Mpl on platelets, leading to the activation of the JAK2-STAT3/5 pathway and platelet aggregation [2].
PF4 is implicated in several thrombotic disorders. It combines with heparin to form an antigen that can produce IgG antibodies, participating in heparin-induced thrombocytopenia (HIT) [3]. In vaccine-induced immune thrombotic thrombocytopenia (VITT), antibodies to PF4 form immune complexes, activating platelets and neutrophils through Fc receptors [2,3,4,5,6,8,9]. The electrostatic interaction between PF4 and negatively charged molecules is crucial in VITT progression, similar to HIT [3,9]. Different types of anti-PF4 antibodies have been proposed, with type 2 (heparin-dependent, platelet-activating) and type 3 (heparin-independent, platelet-activating) associated with severe prothrombotic disorders [4].
In conclusion, Pf4 is vital in platelet activation and coagulation processes. Its role in HIT and VITT has been well-studied, highlighting the importance of understanding Pf4-related immune responses for the diagnosis and treatment of these thrombotic disorders. The research on Pf4 provides insights into the pathogenesis of immune-associated thrombosis and potential therapeutic directions [1,2,3,4,5,6,7,8,9].
References:
1. Warkentin, Theodore E. 2022. Platelet-activating anti-PF4 disorders: An overview. In Seminars in hematology, 59, 59-71. doi:10.1053/j.seminhematol.2022.02.005. https://pubmed.ncbi.nlm.nih.gov/35512902/
2. Buka, Richard J, Montague, Samantha J, Moran, Luis A, Watson, Steve P, Nicolson, Phillip L R. . PF4 activates the c-Mpl-Jak2 pathway in platelets. In Blood, 143, 64-69. doi:10.1182/blood.2023020872. https://pubmed.ncbi.nlm.nih.gov/37883794/
3. Liu, Zhiyan, Li, Longtu, Zhang, Hanxu, Xiang, Qian, Cui, Yimin. 2023. Platelet factor 4(PF4) and its multiple roles in diseases. In Blood reviews, 64, 101155. doi:10.1016/j.blre.2023.101155. https://pubmed.ncbi.nlm.nih.gov/38008700/
4. Greinacher, Andreas, Warkentin, Theodore E. . Thrombotic anti-PF4 immune disorders: HIT, VITT, and beyond. In Hematology. American Society of Hematology. Education Program, 2023, 1-10. doi:10.1182/hematology.2023000503. https://pubmed.ncbi.nlm.nih.gov/38066843/
5. Ngo, Anh T P, Bochenek, Veronica, Gollomp, Kandace. 2023. The immunology of PF4 polyanion interactions. In Current opinion in hematology, 30, 219-229. doi:10.1097/MOH.0000000000000782. https://pubmed.ncbi.nlm.nih.gov/37603711/
6. Yang, Chieh, Wang, Irene, Chitkara, Akshit, Patel, Rushin, Kubba, Samir V. 2024. Anti-PF4 antibodies and their relationship with COVID infection. In Hematology, transfusion and cell therapy, 46, 516-523. doi:10.1016/j.htct.2023.11.012. https://pubmed.ncbi.nlm.nih.gov/38388299/
7. Cai, Zheng, Greene, Mark I, Zhu, Zhiqiang, Zhang, Hongtao. 2020. Structural Features and PF4 Functions that Occur in Heparin-Induced Thrombocytopenia (HIT) Complicated by COVID-19. In Antibodies (Basel, Switzerland), 9, . doi:10.3390/antib9040052. https://pubmed.ncbi.nlm.nih.gov/33050376/
8. Zhang, Yi, Bissola, Anna-Lise, Treverton, Jared, Arnold, Addi, Nazy, Ishac. 2024. Vaccine-Induced Immune Thrombotic Thrombocytopenia: Clinicopathologic Features and New Perspectives on Anti-PF4 Antibody-Mediated Disorders. In Journal of clinical medicine, 13, . doi:10.3390/jcm13041012. https://pubmed.ncbi.nlm.nih.gov/38398325/
9. Liu, Zhi-Yan, Sun, Min-Xue, Hua, Man-Qi, Xiang, Qian, Cui, Yi-Min. 2023. New perspectives on the induction and acceleration of immune-associated thrombosis by PF4 and VWF. In Frontiers in immunology, 14, 1098665. doi:10.3389/fimmu.2023.1098665. https://pubmed.ncbi.nlm.nih.gov/36926331/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
